

Suzanne Nielsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/163071/publications.pdf>

Version: 2024-02-01

157
papers

4,627
citations

109321

35
h-index

128289

60
g-index

160
all docs

160
docs citations

160
times ranked

4411
citing authors

#	ARTICLE	IF	CITATIONS
1	A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 733-737.	1.9	322
2	Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. <i>Pain</i> , 2018, 159, 1932-1954.	4.2	321
3	Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. <i>Neuropsychopharmacology</i> , 2017, 42, 1752-1765.	5.4	190
4	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. <i>Lancet Public Health</i> , The, 2018, 3, e341-e350.	10.0	172
5	Opioid agonist treatment for pharmaceutical opioid dependent people. <i>The Cochrane Library</i> , 2016, , CD011117.	2.8	148
6	Serious morbidity associated with misuse of over-the-counter codeine-ibuprofen analgesics: a series of 27 cases. <i>Medical Journal of Australia</i> , 2010, 193, 294-296.	1.7	130
7	The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 8.	4.2	116
8	The Pain and Opioids IN Treatment study. <i>Pain</i> , 2015, 156, 231-242.	4.2	104
9	Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. <i>Pain Medicine</i> , 2015, 16, 356-366.	1.9	102
10	Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings From Starting Treatment With Agonist Replacement Therapies (START). <i>Journal of Studies on Alcohol and Drugs</i> , 2013, 74, 605-613.	1.0	100
11	Benzodiazepines, Methadone and Buprenorphine: Interactions and Clinical Management. <i>American Journal on Addictions</i> , 2010, 19, 59-72.	1.4	92
12	Prescription drug abuse: from epidemiology to public policy. <i>Journal of Substance Abuse Treatment</i> , 2015, 48, 1-7.	2.8	91
13	Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. <i>Addiction</i> , 2007, 102, 616-622.	3.3	83
14	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. <i>Pain Medicine</i> , 2015, 16, 1745-1758.	1.9	78
15	The source and diversion of pharmaceutical drugs for non-medical use: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2018, 186, 242-256.	3.2	67
16	Identifying and treating codeine dependence: a systematic review. <i>Medical Journal of Australia</i> , 2018, 208, 451-461.	1.7	67
17	Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine. <i>Drugs</i> , 2019, 79, 1395-1418.	10.9	67
18	Trends and characteristics of accidental and intentional codeine overdose deaths in Australia. <i>Medical Journal of Australia</i> , 2015, 203, 299-299.	1.7	63

#	ARTICLE	IF	CITATIONS
19	The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 521-538.	1.9	63
20	Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal. <i>Addiction</i> , 2016, 111, 2177-2186.	3.3	61
21	Stigma and Social Support in Pharmaceutical Opioid Treatment Populations: a Scoping Review. <i>International Journal of Mental Health and Addiction</i> , 2017, 15, 452-469.	7.4	56
22	Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. <i>Lancet Psychiatry</i> , 2015, 2, 314-322.	7.4	55
23	Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 967.	7.4	55
24	The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy. <i>Substance Abuse and Rehabilitation</i> , 2022, Volume 13, 1-12.	4.8	51
25	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305.	3.3	46
26	Buprenorphine pharmacotherapy and behavioral treatment: Comparison of outcomes among prescription opioid users, heroin users and combination users. <i>Journal of Substance Abuse Treatment</i> , 2015, 48, 70-76.	2.8	44
27	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. <i>Pain</i> , 2016, 157, 1489-1498.	4.2	43
28	Prescription drug misuse: Is technology friend or foe?. <i>Drug and Alcohol Review</i> , 2009, 28, 81-86.	2.1	40
29	Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. <i>Drug and Alcohol Dependence</i> , 2016, 162, 79-87.	3.2	40
30	Cohort protocol paper: The Pain and Opioids In Treatment (POINT) study. <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 17.	2.4	39
31	What is known about community pharmacy supply of naloxone? A scoping review. <i>International Journal of Drug Policy</i> , 2016, 32, 24-33.	3.3	39
32	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 587-591.	1.9	39
33	The effect of buprenorphine and benzodiazepines on respiration in the rat. <i>Drug and Alcohol Dependence</i> , 2005, 79, 95-101.	3.2	38
34	A Comparison of Buprenorphine Taper Outcomes Between Prescription Opioid and Heroin Users. <i>Journal of Addiction Medicine</i> , 2013, 7, 33-38.	2.6	37
35	An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 469-494.	1.9	37
36	Etizolam: A rapid review on pharmacology, non-medical use and harms. <i>Drug and Alcohol Review</i> , 2020, 39, 330-336.	2.1	36

#	ARTICLE	IF	CITATIONS
37	The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence.. <i>Experimental and Clinical Psychopharmacology</i> , 2010, 18, 489-497.	1.8	35
38	A systematic review of opioid overdose interventions delivered within emergency departments. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108009.	3.2	35
39	Opportunities and challenges: over-the-counter codeine supply from the codeine consumerâ€™s perspectiveâ€™. <i>International Journal of Pharmacy Practice</i> , 2013, 21, 161-168.	0.6	34
40	Perceived stigma and social support in treatment for pharmaceutical opioid dependence. <i>Drug and Alcohol Review</i> , 2018, 37, 262-272.	2.1	33
41	Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 135-144.	3.2	33
42	Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. <i>Pain Medicine</i> , 2018, 19, 533-540.	1.9	32
43	Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. <i>BMJ Open</i> , 2018, 8, e025204.	1.9	31
44	Factors associated with the development of depression in chronic non-cancer pain patients following the onset of opioid treatment for pain. <i>Journal of Affective Disorders</i> , 2015, 184, 72-80.	4.1	30
45	Pharmaceutical opioid analgesic and heroin dependence: How do treatmentâ€™seeking clients differ in Australia?. <i>Drug and Alcohol Review</i> , 2011, 30, 291-299.	2.1	28
46	Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies. <i>Neuropsychopharmacology</i> , 2022, 47, 1315-1330.	5.4	28
47	Over-the-Counter Codeineâ€™ from Therapeutic Use to Dependence, and the Grey Areas in Between. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 34, 59-75.	1.7	27
48	Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale. <i>Drug and Alcohol Dependence</i> , 2016, 159, 42-52.	3.2	27
49	Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia. <i>Harm Reduction Journal</i> , 2021, 18, 20.	3.2	27
50	Recent increase in detection of alprazolam in Victorian heroinâ€™related deaths. <i>Medical Journal of Australia</i> , 2013, 198, 206-209.	1.7	25
51	Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. <i>American Journal on Addictions</i> , 2015, 24, 667-675.	1.4	25
52	Comparing treatmentâ€™seeking codeine users and strong opioid users: Findings from a novel case series. <i>Drug and Alcohol Review</i> , 2015, 34, 304-311.	2.1	25
53	What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. <i>International Review of Psychiatry</i> , 2018, 30, 91-106.	2.8	25
54	How prescription drug monitoring programs influence clinical decision-making: A mixed methods systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109090.	3.2	25

#	ARTICLE	IF	CITATIONS
55	Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. <i>Drug and Alcohol Review</i> , 2007, 26, 143-151.	2.1	24
56	The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. <i>Medical Journal of Australia</i> , 2013, 199, 696-699.	1.7	24
57	Attitudes in Australia on the upscheduling of over-the-counter codeine to a prescription-only medication. <i>Drug and Alcohol Review</i> , 2018, 37, 257-261.	2.1	23
58	Changes in Australian prescription opioid use following codeine rescheduling: A retrospective study using pharmaceutical benefits data. <i>International Journal of Drug Policy</i> , 2019, 74, 170-173.	3.3	23
59	Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study. <i>International Journal of Drug Policy</i> , 2019, 69, 46-52.	3.3	23
60	Recent trends in heroin and pharmaceutical opioid-related harms in Victoria, Australia up to 2018. <i>Addiction</i> , 2020, 115, 261-269.	3.3	23
61	Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a "moral hazard" associated with naloxone supply. <i>International Journal of Drug Policy</i> , 2022, 100, 103513.	3.3	23
62	A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: Feasibility, tolerability and clinical outcomes. <i>Drug and Alcohol Review</i> , 2013, 32, 88-95.	2.1	22
63	Cocaine Use Reduction with Buprenorphine (CURB): Rationale, design, and methodology. <i>Contemporary Clinical Trials</i> , 2013, 34, 196-204.	1.8	22
64	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2022, 100, 103492.	3.3	22
65	Comparing buprenorphine induction experience with heroin and prescription opioid users. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 285-290.	2.8	21
66	A mapping review of take-home naloxone for people released from correctional settings. <i>International Journal of Drug Policy</i> , 2017, 46, 7-16.	3.3	20
67	Benzodiazepines - Their role in aggression and why GPs should prescribe with caution. <i>Australian Family Physician</i> , 2011, 40, 862-5.	0.5	20
68	Benzodiazepines. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 34, 141-159.	1.7	19
69	Cannabinoids for the treatment of spasticity. <i>Developmental Medicine and Child Neurology</i> , 2019, 61, 631-638.	2.1	19
70	Alprazolam use and related harm among opioid substitution treatment clients " 12 months follow up after regulatory rescheduling. <i>International Journal of Drug Policy</i> , 2016, 36, 104-111.	3.3	18
71	Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia. <i>International Journal of Drug Policy</i> , 2021, 90, 103061.	3.3	17
72	Urine drug screening for early detection of unwitting use of fentanyl and its analogues among people who inject heroin in Sydney, Australia. <i>Drug and Alcohol Review</i> , 2018, 37, 847-850.	2.1	16

#	ARTICLE	IF	CITATIONS
73	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. <i>EClinicalMedicine</i> , 2020, 28, 100592.	7.1	16
74	The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. <i>American Journal on Addictions</i> , 2014, 23, 343-348.	1.4	15
75	Editorial: Changes for codeine. <i>Australian Prescriber</i> , 2018, 41, 2-3.	1.0	15
76	What can Australia learn from the North American opioid crisis? The role of opioid regulation and other evidence-based responses. <i>Drug and Alcohol Review</i> , 2019, 38, 223-225.	2.1	15
77	Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Victoria, Australia from 2013 to 2018. <i>Addiction</i> , 2020, 115, 1075-1087.	3.3	15
78	Life expectancy of people who are dependent on opioids: A cohort study in New South Wales, Australia. <i>Journal of Psychiatric Research</i> , 2020, 130, 435-440.	3.1	15
79	Naloxone rescheduling in Australia: Processes, implementation and challenges with supply of naloxone as a "pharmacist only" over-the-counter medicine. <i>Drug and Alcohol Review</i> , 2018, 37, 450-453.	2.1	13
80	How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 1014-1020.	3.0	13
81	Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 1047-1055.	3.0	13
82	Selective review and commentary on emerging pharmacotherapies for opioid addiction. <i>Substance Abuse and Rehabilitation</i> , 2011, 2, 181.	4.8	12
83	A cross-sectional analysis of over-the-counter codeine use among an Australian sample of people who regularly inject drugs. <i>Drug and Alcohol Review</i> , 2013, 32, 574-581.	2.1	12
84	Current Opioid Access, Use, and Problems in Australasian Jurisdictions. <i>Current Addiction Reports</i> , 2018, 5, 464-472.	3.4	12
85	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 2450-2458.	1.9	12
86	Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives. <i>Drug and Alcohol Review</i> , 2020, 39, 55-65.	2.1	12
87	Pharmaceutical opioid poisonings in Victoria, Australia: Rates and characteristics of a decade of emergency department presentations among nine pharmaceutical opioids. <i>Addiction</i> , 2022, 117, 623-636.	3.3	12
88	Diversion of prescribed opioids by people living with chronic pain: Results from an Australian community sample. <i>Drug and Alcohol Review</i> , 2014, 33, 27-32.	2.1	11
89	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016, 166, 125-133.	3.2	11
90	Drug sourcing and motivations among a sample of people involved in the supply of pharmaceutical drugs in Australia. <i>International Journal of Drug Policy</i> , 2019, 66, 38-47.	3.3	11

#	ARTICLE	IF	CITATIONS
91	Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions. <i>International Journal of Drug Policy</i> , 2022, 99, 103472.	3.3	11
92	Methadone- and buprenorphine-related ambulance attendances: A population-based indicator of adverse events. <i>Journal of Substance Abuse Treatment</i> , 2008, 35, 457-461.	2.8	10
93	Implementing real-time prescription drug monitoring: Are we ready?. <i>Drug and Alcohol Review</i> , 2014, 33, 463-465.	2.1	10
94	Geographic Variation in Health Service Use and Perceived Access Barriers for Australian Adults with Chronic Non-Cancer Pain Receiving Opioid Therapy. <i>Pain Medicine</i> , 2016, 17, 2003-2016.	1.9	10
95	Sleep Quality Among People Living With Chronic Noncancer Pain. <i>Clinical Journal of Pain</i> , 2016, 32, 380-387.	1.9	10
96	Estimating Centre for Disease Control and Prevention-defined overdose risk in people prescribed opioids for chronic non-cancer pain: implications for take-home naloxone provision. <i>Internal Medicine Journal</i> , 2019, 49, 1054-1055.	0.8	10
97	Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study. <i>BMJ Open</i> , 2019, 9, e029170.	1.9	10
98	Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1694-1701.	3.0	10
99	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108464.	3.2	10
100	Characteristics of a nontreatment-seeking sample of over-the-counter codeine users: implications for intervention and prevention. <i>Journal of Opioid Management</i> , 2011, 7, 363-70.	0.5	10
101	Pharmaceutical drugs: The delicate balance between reducing pain and reducing harm. <i>Drug and Alcohol Review</i> , 2011, 30, 233-235.	2.1	9
102	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 758-769.	1.9	9
103	A protocol for a discrete choice experiment: understanding patient medicine preferences for managing chronic non-cancer pain. <i>BMJ Open</i> , 2019, 9, e027153.	1.9	9
104	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020, 10, e034389.	1.9	9
105	Community pharmacy naloxone supply, before and after rescheduling as an over-the-counter drug: sales and prescriptions data, 2014-2018. <i>Medical Journal of Australia</i> , 2020, 212, 314-320.	1.7	9
106	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3092-3104.	2.4	9
107	Correlates of pain in an in-treatment sample of opioid-dependent people. <i>Drug and Alcohol Review</i> , 2013, 32, 489-494.	2.1	8
108	Health service utilisation by people living with chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. <i>Australian Health Review</i> , 2016, 40, 490.	1.1	8

#	ARTICLE	IF	CITATIONS
109	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. <i>Pain Medicine</i> , 2020, 21, e79-e88.	1.9	8
110	â€˜Extreme personal stressâ€™™ and â€˜a lot of painâ€™™: Exploring the physical, mental and social contexts of extramedical pharmaceutical opioid use in Australian paramedic case descriptions. <i>Drug and Alcohol Review</i> , 2020, 39, 870-878.	2.1	8
111	Community use of naloxone for opioid overdose. <i>Australian Prescriber</i> , 2017, 40, 137-140.	1.0	8
112	Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 70-75.	2.1	7
113	A nationwide study of the extent and factors associated with fentanyl use in Australia. <i>Research in Social and Administrative Pharmacy</i> , 2018, 14, 303-308.	3.0	7
114	Correlates of indicators of potential extramedical opioid use in people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Review</i> , 2020, 39, 128-134.	2.1	7
115	What predicts pharmacistsâ€™™ engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 420-429.	2.1	7
116	Key considerations for the implementation of clinically focused Prescription Drug Monitoring Programs to avoid unintended consequences. <i>International Journal of Drug Policy</i> , 2022, 101, 103549.	3.3	7
117	Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. <i>Drug and Alcohol Review</i> , 2022, 41, 841-850.	2.1	7
118	Infrequent detection of unintentional fentanyl use via urinalysis among people who regularly inject opioids in Sydney and Melbourne, Australia. <i>Addiction</i> , 2022, 117, 2331-2337.	3.3	7
119	Letter to the Editor. <i>Drug and Alcohol Review</i> , 2003, 22, 471-473.	2.1	6
120	THE USE OF SUBLINGUAL BUPRENORPHINEâ€“NALOXONE FOR REVERSING HEROIN OVERDOSE: A HIGH-RISK STRATEGY THAT SHOULD NOT BE RECOMMENDED. <i>Addiction</i> , 2008, 103, 2065-2066.	3.3	6
121	Injecting buprenorphineâ€“naloxone film: Findings from an explorative qualitative study. <i>Drug and Alcohol Review</i> , 2015, 34, 623-629.	2.1	6
122	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. <i>Drug and Alcohol Review</i> , 2018, 37, 887-896.	2.1	5
123	What factors contributed to the misconduct of health practitioners? An analysis of Australian cases involving the diversion and supply of pharmaceutical drugs for non-medical use between 2010 and 2016. <i>Drug and Alcohol Review</i> , 2019, 38, 366-376.	2.1	5
124	Risk of discharge against medical advice among hospital inpatients with a history of opioid agonist therapy in New South Wales, Australia: A cohort study and nested crossover-cohort analysis. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108343.	3.2	5
125	Alprazolam use among a sample of Australians who inject drugs: Trends up to six years post regulatory changes. <i>International Journal of Drug Policy</i> , 2020, 79, 102721.	3.3	5
126	Community pharmacistsâ€™™ preparedness to intervene with concerns around prescription opioids: findings from a nationally representative survey. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 411-419.	2.1	5

#	ARTICLE	IF	CITATIONS
127	Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001–2018: Findings from the OATS retrospective cohort study. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108354.	3.2	5
128	The cost and impact of distributing naloxone to people who are prescribed opioids to prevent opioid-related deaths: findings from a modelling study. <i>Addiction</i> , 2022, 117, 1009-1019.	3.3	5
129	Comparing rates and characteristics of emergency department presentations related to pharmaceutical opioid poisoning in Australia: a study protocol for a retrospective observational study. <i>BMJ Open</i> , 2020, 10, e038979.	1.9	4
130	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. <i>JAMA Network Open</i> , 2021, 4, e213059.	5.9	4
131	Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. <i>Drug and Alcohol Review</i> , 2017, 36, 311-316.	2.1	3
132	Benzodiazepine use of community-based violent offenders: a preliminary investigation. <i>Journal of Substance Use</i> , 2017, 22, 295-303.	0.7	3
133	Validation of the OWLS, a Screening Tool for Measuring Prescription Opioid Use Disorder in Primary Care. <i>Pain Medicine</i> , 2020, 21, 2757-2764.	1.9	3
134	Validity and Reliability of the Computer-Administered Routine Opioid Outcome Monitoring (ROOM) Tool. <i>Pain Medicine</i> , 2020, 21, 3645-3654.	1.9	3
135	Unintended consequences of using real time prescription monitoring systems. <i>Medical Journal of Australia</i> , 2020, 213, 142.	1.7	3
136	Feasibility and acceptability of take-home naloxone for people released from prison in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2021, 40, 98-108.	2.1	3
137	A prospective cohort study evaluating the impact of upscheduling codeine in Australia among frequent users of codeine. <i>Addiction</i> , 2022, 117, 677-686.	3.3	3
138	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. <i>Addiction</i> , 2021, 116, 1482-1494.	3.3	3
139	Opioid agonist treatment in the time of fentanyl: What can we learn from emerging evidence?. <i>Drug and Alcohol Review</i> , 2020, 39, 203-204.	2.1	2
140	The price and mark up of pharmaceutical drugs supplied on the black market. <i>International Journal of Drug Policy</i> , 2020, 76, 102626.	3.3	2
141	Efficacy of cannabinoids for treating paediatric spasticity in cerebral palsy or traumatic brain injury: what is the evidence?. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 1007-1007.	2.1	2
142	Commentary on Cairns et al . (2020): Codeine rescheduling—where to from here?. <i>Addiction</i> , 2020, 115, 460-461.	3.3	2
143	Should we be routinely co-prescribing naloxone for patients on long term opioids?. <i>Medical Journal of Australia</i> , 2021, 214, 403-404.e1.	1.7	2
144	Use of pharmacological and nonpharmacological treatments for chronic noncancer pain among people using opioids: a longitudinal cohort study. <i>Pain</i> , 2022, 163, 1049-1059.	4.2	2

#	ARTICLE	IF	CITATIONS
145	Time to address addiction treatment inequality in hospital settings. <i>Lancet Public Health</i> , The, 2021, , .	10.0	2
146	Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain. <i>International Journal of Drug Policy</i> , 2022, 105, 103708.	3.3	2
147	Commentary on Chang <i>et al</i> . (2018): Assessing prescribing volume and patient riskâ€”implementation considerations. <i>Addiction</i> , 2018, 113, 687-688.	3.3	1
148	The case for developing pharmacist workforce capacity in addiction medicine. <i>Journal of Pharmacy Practice and Research</i> , 2019, 49, 505-507.	0.8	1
149	Editorial: Naloxone for opioid toxicity and overdose in the community. <i>Australian Prescriber</i> , 2021, 44, 38-39.	1.0	1
150	Commentary on McCoy <i>et al</i> .: More pieces of the mosaic describing outcomes of the Australian upâ€”scheduling of overâ€”theâ€”counter codeine to prescription only. <i>Addiction</i> , 2022, 117, 687-689.	3.3	1
151	Impact of Removing Nonprescription Codeine in Australia: Protocol for a Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2020, 9, e15540.	1.0	1
152	A prospective, multisite implementation-efficacy trial of a collaborative prescriber-pharmacist model for Medication Assisted Treatment for Opioid Dependence: Protocol for the EPIC-MATOD study. <i>Research in Social and Administrative Pharmacy</i> , 2021, , .	3.0	1
153	The Overdose Response with Take Home Naloxone (<sc>ORTHN</sc>) project: Evaluation of health worker training, attitudes and perceptions. <i>Drug and Alcohol Review</i> , 2022, 41, 1085-1094.	2.1	1
154	Comparing opioid types in the persistence of opioid use following surgical admission: a study protocol for a retrospective observational linkage study comparing tapentadol and oxycodone in Australia. <i>BMJ Open</i> , 2022, 12, e060151.	1.9	1
155	Prescribing and Dispensing of Benzodiazepines. , 2016, , 283-292.		0
156	Commentary on McDonald <i>et al</i> . (2018): Intranasal naloxoneâ€”from the laboratory to the real world. <i>Addiction</i> , 2018, 113, 494-495.	3.3	0
157	Characteristics of oxycodoneâ€”related ambulance attendances: analysis of temporal trends and the effect of reformulation in Victoria, Australia from 2013 to 2018. <i>Addiction</i> , 2021, 116, 2233-2241.	3.3	0